Note: Data are presented as odds ratios with 95% confidence intervals. Analyses adjusted for patient age, sex, year, admission source, admission urgency, myocardial infarction, diabetes, chronic obstructive pulmonary disease, hypertension, renal dysfunction, congestive heart failure, peripheral vascular disease, concomitant valve repair, use of internal mammary graft(s), and same admission percutaneous coronary intervention.
Objective: To evaluate the association between annual hospital coronary artery bypass graft (CABG) surgery volume and in-hospital mortality. Summary Background Data: The Leapfrog Group recommends health care purchasers contract for CABG services only with hospitals that perform Ն500 CABGs annually to reduce mortality; it is unclear whether this standard applies to current practice. Methods: We conducted a retrospective analysis of the National Inpatient Sample database for patients who underwent CABG in 1998 -2000 (n ϭ 228,738) at low cases/year), medium (250 -499 cases/year), and high (Ն500 cases/year) CABG volume hospitals. Crude in-hospital mortality rates were 4.21% in lowvolume hospitals, 3.74% in medium-volume hospitals, and 3.54% in high-volume hospitals (trend P Ͻ 0.001). Compared with patients at high-volume hospitals (odds ratio 1.00, referent), patients at lowvolume hospitals remained at increased risk of mortality after multivariable adjustment (odds ratio 1.26, 95% confidence interval ϭ 1.15-1.39). The mortality risk for patients at medium-volume hospitals was of borderline significance (odds ratio 1.11, 95% confidence interval ϭ 1.01-1.21). However, 207 of 243 (85%) of lowvolume and 151 of 169 (89%) of medium-volume hospital-years had risk-standardized mortality rates that were statistically lower or comparable to those expected. In contrast, only 11 of 169 (6%) of high-volume hospital-years had outcomes that were statistically better than expected. Conclusions: Patients at high-volume CABG hospitals were, on average, at a lower mortality risk than patients at lower-volume hospitals. However, the small size of the volume-associated mortality difference and the heterogeneity in outcomes within all CABG volume groups suggest individual hospital CABG volume is not a reliable marker of hospital CABG quality.
(Ann Surg 2004;239: 110 -117) P atients who undergo coronary artery bypass graft (CABG) surgery at higher-volume hospitals have been found to have better outcomes than patients treated at lower-volume hospitals. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Based on this evidence, popular press reports 14 -16 and several advocacy groups have endorsed CABG volume as a proxy for hospital CABG quality. [17] [18] [19] In addition, the Leapfrog Group recommends health care purchasers consider hospital volume when contracting for CABG. The Leapfrog Group explicitly frames the use of a hospital CABG volume minimum as a matter of patient safety 20 and estimates that 1486 deaths may be averted by referring CABG patients to hospitals that perform Ն500 procedures annually. 21, 22 This specific volume threshold is derived from an evaluation of the association of hospital CABG volume and in-hospital mortality based on patents hospitalized in New York in 1989. 7 The past decade, however, has witnessed notable changes in CABG practice. Technical modifications, including the increased use of internal mammary artery grafts, warm cardioplegia, off-pump surgery, 23, 24 and the diffusion of CABG to higher-risk patient populations, 25, 26 raise the possibility that a hospital CABG volume minimum of 500 cases may no longer be appropriate. No study, to our knowledge, has assessed the association of hospital CABG volume and patient outcomes in an unselected, nationally representative patient population.
To address this issue, we evaluated the association between annual hospital CABG volume and in-hospital mortality in a national cohort of patients who underwent CABG between 1998 and 2000. To assess the potential effectiveness of the Leapfrog Group's hospital CABG volume minimum, we examined whether patients treated at hospitals with at least 500 cases had lower mortality rates than those at hospitals with lower CABG volumes, and measured hetero-geneity in hospital risk-standardized outcomes within CABG volume groups.
MATERIALS AND METHODS

National Inpatient Sample
Our analysis was based on the Nationwide Inpatient Sample (NIS), a hospital discharge database, from the Agency for Healthcare Research and Quality's Health Care Utilization Project. 27 As the largest publicly available allpayer inpatient database in the United States, the NIS contains administrative records for all hospitalizations in a randomly selected national sample of nongovernmental, acute care hospitals. The 2000 NIS contains information on more than 7.5 million discharges from nearly 1000 hospitals in 28 states, corresponding to nearly 20% of all admissions to U.S. nonfederal hospitals. 28 The public use release of the NIS contains de-identified, hospitalization-level data, including information on primary and secondary diagnoses, demographic characteristics, procedure use, length of stay, payer, total charges, and admission and discharge status. Our study pooled data from the 1998, 1999, and 2000 NIS releases.
Study Sample
We restricted our analysis to hospitalizations in which a patient had a procedure code indicating a CABG (International Classification of Diseases, 9th ed. Clinical Modification [ICD-9-CM] codes 36.10 -36.2). Of the 21 million records in the 1998, 1999, and 2000 NIS, 228,974 indicated a CABG during hospitalization. We excluded patients under the age of 18 years (N ϭ 33) and neonatal or obstetric admissions (n ϭ 14) to restrict our evaluation to an adult population. Hospitalizations with missing data for sex (n ϭ 17), age (n ϭ 7), or mortality (n ϭ 83) were also excluded. We excluded records of patients (n ϭ 86) treated at any of the 73 hospitals with fewer than 12 CABGs coded in any year to prevent the inclusion of procedures that may have reflected administrative data coding errors. The final study cohort consisted of 228,738 admissions from 573 hospital-years of data (393 unique hospitals).
Hospital CABG Volume Groups
To assess the validity of the annual hospital CABG volume threshold of 500 cases recommended by the Leapfrog Group, 17 we divided our cohort into three groups. Hospitals with fewer than 500 cases were divided into those with 12 to 249 cases (hereafter referred to as low volume) and 250 to 499 cases (medium volume) to distinguish true low providers from medium-volume providers that approached the volume requirement. Hospitals with at least 500 annual cases (high volume) were categorized as the single group of providers who met the Leapfrog Group's recommended threshold.
Statistical Analysis
Patient characteristics, including demographics, admission type, comorbidities, and payer, were compared across the three hospital CABG volume groups using global 2 analyses for categorical variables and analyses of variance for continuous variables.
The principal study outcome was in-hospital mortality. We compared crude rates of mortality across all three hospital CABG volume groups using global 2 and test of trend analyses. Unadjusted logistic regression analyses evaluated the discrimination for in-hospital mortality provided by hospital CABG volume using the c-statistic. 29 We assessed the consistency of the association between hospital CABG volume and mortality when stratifying by sex, age, concomitant valve repair, use of an internal mammary graft, history of diabetes, myocardial infarction (MI) during admission, admission type, admission source, year, and hospitalization in a CABG certificate of need state.
Multivariable logistic regressions employing generalized estimating equations were conducted to assess the independent association of hospital CABG volume and patient mortality accounting for the clustered nature of the study sample (admissions within hospital-year clusters). Patient characteristics incorporated in the multivariable model, derived from administrative data-based evaluations of CABG, 30, 31 included the following: sex, age, year, admission source, urgency of admission, principal diagnosis of MI (ICD-9-CM code 410), secondary diagnosis of MI, any other non-MI coronary disease diagnosis (ICD-9-CM codes 411-414), diabetes (ICD-9-CM code 250), chronic obstructive pulmonary disease (ICD-9-CM codes 490 -496), hypertension (ICD-9-CM codes 401-405), renal dysfunction (ICD-9-CM codes 580 -586), congestive heart failure (ICD-9-CM codes 428, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91), peripheral vascular disease (ICD-9-CM codes 440, 443), concomitant valve repair (ICD-9-CM code 35), use of an internal mammary graft (ICD-9-CM code 36.15, 36.16), and a same admission percutaneous coronary intervention (ICD-9-CM procedure code 36.00 -36.06, 36.09). Because we specifically sought to examine the value of the current hospital CABG volume recommendation of 500 cases, we compared mortality among patients at medium-volume (250 -499 cases) and high-volume (Ն500 cases) hospitals.
Risk-standardized mortality rates were calculated for each hospital by dividing the hospital's observed mortality rate by its expected mortality rate, as predicted by the covariates employed in our multivariable model (excluding hospital CABG volume), and multiplying this ratio by the cohort's mortality rate (3.68%). The distribution of hospital riskstandardized mortality rates was plotted as a function of hospital CABG volume. We computed the proportion of hospitals in each CABG volume group that had a risk-standardized mortality rate significantly below the cohort's rate (significantly better outcomes than expected), a riskstandardized mortality rate statistically comparable to the cohort's rate (outcomes similar to those expected), and those with a risk-standardized mortality rate that was significantly greater than the cohort's rate (significantly worse outcomes than expected). 32 All analyses were conducted using SAS 8.2 (SAS Institute, Cary, NC) and Stata 7.0 (Stata Corporation, College Station, TX). Our analysis of the NIS database was approved by the University of Pennsylvania Institutional Review Board.
RESULTS
Patient Characteristics
Of the 228,738 hospitalizations in the study cohort, 36,587 (16%) were treated at low-volume hospitals, 59,437 (26%) at medium high-volume hospitals, and 132,714 (58%) at high-volume hospitals ( Table 1 ). Patients at lower-volume hospitals were slightly younger on average and were more commonly white and treated in non-certificate of need states. The proportions of patients with Medicare insurance, who arrived by interhospital transfer, or who had either an elective admission, a procedure that included use of an internal mammary graft, or a concomitant valve procedure were greater across successively larger hospital CABG volume groups. The proportions of patients who were male, or who had a history of hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, renal dysfunction, heart failure, or peripheral vascular disease were generally comparable across the three hospital CABG volume groups.
CABG Volume and Crude In-Hospital Mortality
Crude in-hospital morality rates ranged from 4.21% for patients at low-volume hospitals to 3.54% for patients at high-volume hospitals (P Ͻ 0.001). Patients at mediumvolume hospitals had higher in-hospital mortality rates than patients at high-volume hospitals (3.74% vs. 3.54%, P ϭ 0.016) ( Table 2 ). Hospital CABG volume alone provided only modest discrimination for in-hospital mortality (c statistic ϭ 0.52).
The association between hospital CABG volume category and crude mortality differed based on whether the patient underwent a concomitant valve repair procedure (P ϭ 0.02 for interaction). Although mortality differed for patients at medium-volume and high-volume hospitals who underwent an isolated CABG (3.16% vs. 2.75%, P Ͻ 0.001), there was no difference in mortality rates between patients who underwent a valve repair (9.26% vs. 9.62%, P ϭ 0.44). The crude association of hospital CABG volume and mortality was otherwise consistent across patient sex, age, diabetes status, use of an internal mammary artery graft, arrival by transfer, type of admission, year, and treatment in a certificate of need state ( Table 2 ).
Adjusted Analysis
Patients at low-volume hospitals remained at increased risk of in-hospital mortality (odds ratio [OR] 1.26, 95% confidence interval [CI] 1.15-1.39) after multivariable adjustment compared with patients at high-volume hospitals (referent) ( Table 3 ). Patients at medium-volume hospitals had an increased mortality risk of borderline statistical significance (OR 1.11, 95% CI 1.01-1.21). The crude interaction for in-hospital mortality between hospital CABG volume and concomitant valve procedure was not significant after multivariable adjustment (P ϭ 0.21). Findings were unchanged when analyses were repeated evaluating interactions for patient sex, age, MI, diabetes, type and urgency of admission, treatment in a certificate of need state, and year (results not shown).
Risk-standardized mortality rates were generally lower among patients treated in higher-volume CABG hospitals, although there was large variation in the distribution of hospital risk-standardized mortality rates across hospital CABG volume ( Fig. 1 ). Eight of 243 (3.3%) low, 11 of 169 (6.5%) medium, and 26 of 161 (16.1%) high CABG volume hospital-years had a significantly lower risk-standardized mortality rate than the cohort rate (ie, outcomes better than expected). In contrast, 36 (14.8%) low, 18 (10.7%) medium, and 18 (11.2%) high CABG volume hospitals had significantly higher risk-standardized mortality rates compared with the cohort rate (ie, outcomes worse than expected). All other hospitals had risk-standardized mortality rates that were comparable to the cohort rate (ie, outcomes similar to those expected) ( Table 4 ).
DISCUSSION
Annual hospital CABG volume provided limited information to differentiate between hospitals' CABG mortality rates in a nationally representative cohort of 20% of hospitalizations between 1998 and 2000. Although patients at high-volume CABG hospitals had, on average, a lower risk of in-hospital mortality than patients at medium-volume CABG hospitals, the magnitude of this effect (11%) was smaller than the 27% risk reduction assumed by the Leapfrog Group for high-volume hospitals meeting their volume standard. 22 In addition, we found considerable heterogeneity in risk-standardized mortality rates across hospital CABG volume. Specifically, most medium and low CABG volume hospitals achieved comparable or better outcomes than predicted and most high-volume hospitals reported comparable or poorer outcomes than expected, suggesting that the Leapfrog Group's hospital CABG volume minimum would misrepresent hospital CABG quality of care. While our findings 
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Hospital CABG Volume and Mortality support the general association of hospital CABG volume and patient outcomes, 1-13 the modest volume effect and heterogeneity in outcomes within hospital volume groups raise concerns about the adoption of a hospital CABG volume recommendation of 500 annual cases.
It is unclear what processes may have produced a smaller average volume-associated effect than previously reported. A true reduction may have resulted from the increased use of CABG, in both annual frequency and the cumulative experience of CABG providers, in the past decade. Tracking and publicly reporting CABG outcomes may have reduced the volume-associated mortality benefit by encouraging the dissemination of "best practices." 33 Alternatively, reports of poorer outcomes at lower-volume CABG hospitals may have resulted in poorer quality low-volume providers suspending their CABG services. 34 New low-volume CABG programs may also have been of higher quality than existing low-volume hospitals. It is also conceivable, though unlikely, that low-volume hospitals with poorer outcomes may have increased their CABG volumes and migrated into higher-volume groups without improving their outcomes. Our analysis demonstrates that patients at higher-volume hospitals had lower mortality rates on average than patients at lower-volume hospitals. However, this general association is likely insufficient by itself to justify a hospital CABG volume-based threshold. An important question is whether the absolute mortality difference across hospital CABG volume groups is large enough to support referring patients exclusively to high-volume hospitals. 17 The 11% higher relative odds in mortality for patients at mediumvolume hospitals compared with high-volume hospitals translates into an absolute risk difference of only 0.3% to 0.4%. One survey found that 45% of elective surgery patients were willing to tolerate a 3% absolute mortality increase to see a surgeon of their choosing rather than be referred to a regional surgery center, 35 suggesting that patients may not find mortality differences of the magnitude we observed to be compelling.
The size of any absolute hospital volume-associated mortality benefit depends on a patient's baseline mortality risk. If we assume that a 1% reduction in absolute mortality were the minimum necessary to justify volume-based referral, only patients with an absolute mortality risk of 10% or higher at medium-volume hospitals would meet this criterion. However, no patient group we tested at medium-volume hospitals had an absolute mortality risk this large. In contrast, patients at low-volume hospitals with a mortality risk of 4% or higher would experience, on average, a 1% point or greater absolute mortality reduction. Because a large proportion of patients at low-volume hospitals had a baseline mortality risk close to 4%, volume-based referral may merit consideration.
A hospital CABG volume-based referral policy requires that CABG volume be an accurate means of differentiating between hospitals' CABG quality. The poor discrimination provided by hospital CABG volume and the marked heterogeneity in risk-standardized mortality rates across hospital CABG volume suggest this is not the case. Of particular concern are the 207 of 243 (85%) low-volume hospital-years and 151 of 169 (89%) medium-volume CABG hospital-years with similar to or better than expected risk-standardized mortality rates and the 18 of 161 (11%) high-volume hospital-years with poorer than expected risk-standardized mortality rates. Similar findings in other studies of hospital CABG volume 5, 6, 36, 37 confirm that a volume-based policy may inadvertently harm low-volume CABG providers that are performing well, 38 and ignore poorly performing high-volume CABG providers. A hospital volume-based referral policy provides no guarantee that patients treated at high-volume hospitals will achieve superior outcomes. Consequently, expected mortality reductions reported by Leapfrog 39 and others 40, 41 may represent an optimistic assessment of the benefits of volume-based referral.
Uncertainty about the benefits of a hospital CABG volume threshold is accompanied by concerns about the potential harms of a volume-based referral strategy. 42 By concentrating CABG services among fewer providers, access may be affected adversely, and less competition may result in higher CABG prices. 43, 44 Adoption of a volume threshold could lead to providers' treating patients with borderline indications for CABG to increase hospital volume. Furthermore, the proposed mortality benefits are based on statistical FIGURE 1. Risk-standardized mortality rates by CABG volume. Black circles denote hospitals with risk-standardized mortality rates that are significantly higher than the cohort rate; white circles denote hospitals with risk-standardized mortality rates that are statistically comparable to the cohort rate; and black triangles denote hospitals with risk-standardized mortality rates that are lower than the cohort rate. The solid black line denotes the overall cohort's mortality rate (3.68%). inferences from cross-sectional analyses and do not reflect any real world experience with volume-based patient referral. Use of the NIS database improves on previous studies of CABG volume. The NIS contains data from a random selection of hospitals in multiple states over a recent 3-year period, comprising approximately 20% of all U.S. hospitalizations, and thus reflects contemporary CABG practice. This comprehensive cohort permits the evaluation of CABG volume and outcomes across a variety of practice environments and provides a more generalizable evaluation than voluntary or regional registries. In contrast to previous national analyses of CABG volume that studied Medicare patients, the NIS contains data on patients of all ages. The inclusion of non-Medicare patients is important because nearly half of all CABG patients are younger than 65 years. 45 Despite these advantages, our analysis has limitations. First, the NIS database is based on administrative data and lacks important clinical details, including descriptions of patient anatomy and type of bypass graft, and may be susceptible to hospital-based variations in data coding practices. Previous studies, however, have demonstrated that administrative databases contain sufficient information to evaluate hospital differences in quality of CABG care. 30, 31 In addition, more clinically detailed risk adjustment has been associated with a reduction in the effect of volume on outcomes, suggesting our administrative data-based analysis may in fact overstate the association of volume and patient outcomes. 46 However, to the extent higher-volume hospitals treated patients who were higher risk based on characteristics we could not measure, our results may underestimate the volumemortality association. Nevertheless, our findings merit further study in more clinically detailed databases, such as that maintained by the Society of Thoracic Surgeons (www.sts.org, accessed June 18, 2003) . Second, we evaluated inhospital mortality alone and could not assess other patient outcomes, including procedural complications or outcomes after discharge. However, the Leapfrog Group's hospital CABG volume recommendation is predicated exclusively on a mortality reduction, not improvement on other outcomes. 44 Third, the NIS does not collect information on individual physicians, which precludes the consideration of the effect of physician volume on hospital volume effects. Individual surgeon CABG volume is arguably of importance for establishing a hospital volume threshold only if it explains the association between hospital CABG volume and outcomes. Such a finding would suggest that efforts to improve CABG outcomes should focus on establishing surgeon, and not hospital, volume minimums. Finally, the NIS does not contain unique patient identifiers. The possible inclusion of multiple patient admissions in our cohort may violate statistical assumptions of independence, although few patients likely undergo two or more CABGs in a 3-year span.
Our evaluation of a national cohort of CABG patients found a general association between higher CABG volume and lower mortality rates. Although CABG patients at hospitals with Ն500 cases had lower mortality rates than patients at medium-volume hospitals, the overall mortality difference was small. Further, the limited discrimination provided by hospital CABG volume and substantial heterogeneity in hospitals' risk-standardized mortality rates within CABG volume groups raise questions about whether volume is a reliable measure of hospital CABG quality. Our findings suggest that choosing CABG hospitals solely by means of a CABG volume threshold of 500 cases may not be an effective means of ensuring high quality care.
